Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 20, 2019. The document serves as a transaction notification regarding securities transactions by a Person Discharging Managerial Responsibilities (PDMR), specifically Mr. J Ford, SVP & General Counsel.
Key Financial Metrics
The filing text does not provide corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to reporting specific insider trading activities.
| Transaction Type | Instrument | Volume | Price | Date |
|---|---|---|---|---|
| Option Exercise | ADSs (Incentive & Non-Qualified) | 11,870 | $37.32 | 2019-02-19 |
| Sale | ADSs | 11,870 | $41.22 | 2019-02-19 |
| Sale | ADSs | 11,884 | $41.22 | 2019-02-19 |
| Sale | Ordinary Shares | 1 | £15.66 | 2019-02-19 |
Material Changes
The filing does not report material changes to the company's financial position or operations. It details a single day of activity where Mr. Ford exercised stock options granted in 2010 and subsequently sold the resulting shares on the New York Stock Exchange and London Stock Exchange.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, future guidance, outlook, risk factors, or contingencies. It is a regulatory disclosure of a specific transaction event.
Key Facts for Investor Verification
- Insider Activity: Mr. J Ford exercised options on 11,870 ADSs at $37.32 and sold them at $41.22, realizing a gain on the spread.
- Transaction Volume: A total of 23,754 ADSs were sold by the executive on February 19, 2019 (11,870 from option exercise and 11,884 from existing holdings).
- Market Venues: Transactions occurred on both the New York Stock Exchange (XNYS) and the London Stock Exchange (XLON).
- Scope Limitation: This document does not reflect GSK's overall financial performance for the period; investors should refer to Form 20-F or quarterly reports for corporate financial data.